Therapeutic drug monitoring involves measuring drug concentrations in plasma, serum or blood. This information is used to individualise dosage so that drug concentrations can be maintained within a target range. By combining knowledge of pharmaceutics, pharmacokinetics, and pharmacodynamics, therapeutic drug monitoring enables the assessment of the efficacy and safety of a particular medication in a variety of clinical settings. The aim of therapeutic drug monitoring is to individualize therapeutic regimens for optimal patient benefit.
Recent growth of therapeutic drug monitoring has been fuelled by five key factors including rise in the demand for better healthcare from urban population in the developed countries, focus on cost effectiveness of therapeutic drug monitoring, increased knowledge of pharmacokinetics and pharmacokinetics of drugs among the clinicians, rapid increase in the prevalence of complex neurological diseases and cancer, increasing investments in research and development of novel drugs and vaccines. Furthermore, advanced treatment therapies such as pharmacogenomics, gene testing, and proteomics is further expected to boost the growth of market.
The report analyses the global therapeutic drug monitoring market based on product, technology, class of drug, end user and geography.
Based on product, the market is segmented into consumables and equipment’s. The segment can be further segmented into number of equipment such as immunoassay analyzers, spectrophotometers, and chromatograms. Increasing preference for technologically advanced services, cost-effective kits, increasing demand for new technology-based and the extensive use of these reagents in the R&D area are some of the factors responsible for its lucrative growth for the significant growth of the consumable segment.
The drug monitoring market by technology is segmented into Immunoassays and chromatography-mass spectroscopy. The Immunoassay segment is further classified into fluorescence immunoassays, radioimmunoassay, chemiluminescent immunoassays, and colorimetric immunoassays among others. Further, chromatography-mass spectroscopy is sub classified into liquid chromatography/mass spectrometry and gas chromatography-mass spectrometry. Numerous immunoassay methods are now in routine use for therapeutic drug monitoring of drugs and metabolites. Most methods of immunoassays are homogeneous immunoassays with excellent specificity, accuracy, and precision. In addition, these assays are readily automated, and commercial versions of theses reagents are available with dedicated instrumentation. The availability of highly specific and reliable immunoassays, the requirement of minimal training to handle the equipment and the rising adoption rate of the advanced techniques are the factors leading to the growth of immunoassay market segment.
On the basis of drug class, the market can be segmented into antiepileptics, antibiotics, Antimanics, antiarrhythmic drugs, bronchodilators, immunosuppressants, and others. Antiepileptics are the class of drugs, most often prescribed for the management of epilepsy. Antiepileptic drugs are capable of depressing abnormal neuronal discharges in the central nervous system, which may otherwise result in seizures. Increasing prevalence of epilepsy and seizures and the resultant rapid growth in the number of Anti-epileptic drugs are the factors contributing to the growth of the antiepileptics drug segment in the market.
The end-use segment includes hospital labs, private labs, and others (research institutes, academic institutes, and pharmaceutical companies). Most diagnostic tests are carried out in hospitals or hospital-attached laboratories due to the availability appropriate equipment, skilled staff as well as the availability of accurate patient information, such as age, metabolism, ethnicity, and drug performance history. The increasing use of computerized entry of patient history and information records is expected to further improve the TDS service in the hospitals.
By geography, the global therapeutic drug monitoring market is studied across the countries of key regions such as, North America, Europe, Asia Pacific, and Rest of the world. North America comprises U.S., Canada and Mexico, whereas Europe would primarily cover Germany, the U.K., France, Italy and Rest of Europe. The key countries included under Asia Pacific are China, Japan, India, and Rest of Asia Pacific. Rest of the world include Latin America and Middle East and Africa (MEA). North America is estimated to hold the largest share of the global therapeutic drug monitoring (TDM) market owing to the high rate of organ transplantation coupled with the strong regional economics and presence of superior health care base. However, Lucrative growth in the Asia Pacific region over the forecast period attributable to the presence of unmet needs and the continuous efforts of the government to provide low-cost services with the aim of promoting individualized dosage patterns for organ transplantation cases as well as to growing emphasis on research and development in the health care sector.
Some prominent players of the therapeutic drug monitoring market include F. Hoffmann,Roche AG, Siemens Healthcae GmbH, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Bayer AG ,Abbott Laboratories, Inc., Agilent Technologies, Inc., Randox Laboratories, bioMérieux, Inc., and Alere, Inc. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition and companies are introducing new-generation, clinically-effective drug monitoring devices that are portable and miniaturized so as to gain a competitive edge in the market.
The main purpose of therapeutic drug monitoring is refining patient care by individually adjusting the drug dosage for better outcomes. Therapeutic drug monitoring is regarded as a module of personalized medicine that interacts with various other disciplines such as pharmacogenomics and pharmacokinetics. The global therapeutic drug monitoring market showed significant growth over the last few years and is projected to grow at a robust CAGR during the forecast period. The global Therapeutic Drug Monitoring market is segmented based on product, technology, class of drug, application and geography. Based on product, the market is segmented into consumables and equipment’s. The Equipment segment sub classified into number of equipment such as immunoassay analysers, spectrophotometers, and chromatograms. By Technology, market segmented into immunoassays and proteomic technology. The Immunoassay segment is further classified into Fluorescence Immunoassays, Radioimmunoassay, Chemiluminescent Immunoassays, and colorimetric Immunoassays among others. Further, chromatography-mass spectroscopy is sub classified into Liquid Chromatography/Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectrometry. Also, on the basis of drug class, the market can be segmented into antiepileptics, antibiotics, antimanics, antiarrhythmic drugs, bronchodilators, immunosuppressant, and others. The end-use segment includes hospital labs, private labs, and others (research institutes, academic institutes, and pharmaceutical companies). North America accounted for the largest market share of therapeutic drug monitoring in 2018, dominated by the North America. The growth in this region is supported by high rate of organ transplantation coupled with the strong regional economics and presence of superior health care base
Why to buy this report: